S
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Price:
110.6
HKD
12.34%
Market Closed
Market Cap:
HK$24.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
|
CN |
|
Northwest Natural Holding Co
NYSE:NWN
|
US |
|
Hallenstein Glasson Holdings Ltd
NZX:HLG
|
NZ |
|
DSV A/S
F:DS81
|
DK |
|
RBL Bank Ltd
NSE:RBLBANK
|
IN |
|
C
|
Canadian Natural Resources Ltd
SWB:CRC
|
CA |
|
H
|
Himalaya Energi Perkasa Tbk PT
IDX:HADE
|
ID |
|
H
|
Honliv Healthcare Management Group Co Ltd
HKEX:9906
|
CN |
|
Schouw & Co A/S
CSE:SCHO
|
DK |
|
T
|
Tilray Brands Inc
TSX:TLRY
|
US |
|
Y
|
Yuanbao Inc
NASDAQ:YB
|
CN |
|
Companhia Brasileira de Distribuicao SA
BOVESPA:PCAR3
|
BR |
|
OAR Resources Ltd
ASX:OAR
|
AU |
|
Ricardo PLC
LSE:RCDO
|
UK |
|
TV Tokyo Holdings Corp
TSE:9413
|
JP |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of SciClone Pharmaceuticals (Holdings) Ltd.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
Competitors Multiples
SciClone Pharmaceuticals (Holdings) Ltd Competitors
SciClone Pharmaceuticals (Holdings) Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
S
|
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
|
24.9B HKD | 58.3 | 163.9 | 14.2 | 15.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD | 13.8 | 43.6 | 29.4 | 31.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 5.3 | 30.3 | 16.7 | 23.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD | 4.7 | 16.7 | 10.3 | 12.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.5B CHF | 5.2 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
